<DOC>
	<DOC>NCT00193388</DOC>
	<brief_summary>In this phase II trial, we will evaluate the weekly schedule of topotecan in the second-line treatment of patients with small cell lung cancer</brief_summary>
	<brief_title>Weekly Topotecan in the Second-Line Treatment of Small Cell Lung Cancer</brief_title>
	<detailed_description>Upon determination of eligibility, all patients will be receive: - Topotecan</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>To be included in this study, you must meet the following criteria: Small Cell Lung cancer Progression after one previous regimen Measurable or evaluable disease Able to perform activities of daily living with assistance Adequate bone marrow, liver and kidney function No more than three previous courses of radiation therapy Accessible for treatment and follow up Must give written informed consent prior to study entry You cannot participate in this study if any of the following apply to you: Central nervous system involvement Serious or active infection Serious underlying medical condition Other active neoplasms Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>